

DRUG PRIOR AUTHORIZATION COMMITTEE

March 21, 2019

AGENDA

MO HealthNet Division, Second Floor
615 Howerton Court, Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:10	Minutes Review	Discussion/Approval
10:10 - 10:25	Pharmacy Program/ Budget Update	Mitch Ruth
10:25 - 10:30	DUR Update	Mark Roaseau

Old Business

10:30 – 10:45	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Mark Roaseau
---------------	--	--------------

New Business

10:45 – 11:15	B. Proposed Actions- New Drug/Product Review (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Fiscal Edit/Step Therapyiii. PDL Productsiv. Prior Authorization<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Mark Roaseau
---------------	---	--------------

11:15 – 11:45	C. <u>Clinical Edits</u> <ul style="list-style-type: none">i. Benzodiazepines Clinical Edit (New)<ul style="list-style-type: none">• Discussion• Public Hearing• Decisionii. Clobazam Clinical Edit (New)<ul style="list-style-type: none">• Discussion• Public Hearing• Decisioniii. Epidiolex Clinical Edit (New)<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
---------------	---	--

iv. Morphine-Milligram-Equivalent Accumulation Edit

- Discussion
- Public Hearing
- Decision

v. Nocturnal Polyuria Clinical Edit (New)

- Discussion
- Public Hearing
- Decision

vi. Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis (hATTR) Clinical Edit (New)

- Discussion
- Public Hearing
- Decision

vii. Systemic Antifungals Clinical Edit (New)

- Discussion
- Public Hearing
- Decision

11:45 – 1:30

D. Preferred Drug List (PDL)

I. Actinic Keratosis Agents – Topical

- Discussion
- Public Hearing
- Decision

II. Androgenic Agents – Topical

- Discussion
- Public Hearing
- Decision

III. Antibiotics - Inhaled

- Discussion
- Public Hearing
- Decision

IV. Antifungals (Onychomycosis Agents) – Oral

- Discussion
- Public Hearing
- Decision

V. Antifungals – Topical

- Discussion
- Public Hearing
- Decision

VI. Antihistamines – Intranasal

- Discussion
- Public Hearing
- Decision

- VII. Antihistamines – Low-Sedating (2nd Generation)**
 - Discussion
 - Public Hearing
 - Decision
- VIII. Antihistamines/Decongestants – Low-Sedating**
 - Discussion
 - Public Hearing
 - Decision
- IX. Antihistamines – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision
- X. Antiparasitics – Topical**
 - Discussion
 - Public Hearing
 - Decision
- XI. Antivirals - Topical**
 - Discussion
 - Public Hearing
 - Decision
- XII. Atopic Dermatitis Agents (Topical Immunomodulators)**
 - Discussion
 - Public Hearing
 - Decision
- XIII. Benzoyl Peroxide/Antibiotic Combinations – Topical**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Beta-Adrenergic Agents (Long-Acting)**
 - Discussion
 - Public Hearing
 - Decision
- XV. Beta-Adrenergic Agents – Nebulized**
 - Discussion
 - Public Hearing
 - Decision
- XVI. Beta-Adrenergic Agents (Short-Acting)**
 - Discussion
 - Public Hearing
 - Decision

- XVII. Calcitonin Gene-Related Peptide Inhibitor Agents (New)**
 - Discussion
 - Public Hearing
 - Decision
- XVIII. COPD Anticholinergic Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIX. Corticosteroids – Intranasal**
 - Discussion
 - Public Hearing
 - Decision
- XX. Corticosteroids – Oral Inhaled**
 - Discussion
 - Public Hearing
 - Decision
- XXI. Corticosteroids – Ophthalmic “Soft” Steroids and Intravitreal Implants (New)**
 - Discussion
 - Public Hearing
 - Decision
- XXII. Corticosteroids – Topical**
 - Discussion
 - Public Hearing
 - Decision
- XXIII. Cough & Cold Products**
 - Discussion
 - Public Hearing
 - Decision
- XXIV. Cough & Cold Opioid Combination Products**
 - Discussion
 - Public Hearing
 - Decision
- XXV. Epinephrine Self-Injectable Products**
 - Discussion
 - Public Hearing
 - Decision
- XXVI. Fluoroquinolones – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision

- XXVII. Fluoroquinolones – Otic**
 - Discussion
 - Public Hearing
 - Decision
- XXVIII. Herpes Antivirals – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XXIX. Leukotriene Modifiers – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XXX. Mast Cell Stabilizers – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision
- XXXI. NSAIDs – Ophthalmic**
 - Discussion
 - Public Hearing
 - Decision
- XXXII. Pancreatic Enzymes**
 - Discussion
 - Public Hearing
 - Decision
- XXXIII. Prostaglandin Agonists (Glaucoma Agents)**
 - Discussion
 - Public Hearing
 - Decision
- XXXIV. Psoriasis Agents – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XXXV. Psoriasis Agents – Topical**
 - Discussion
 - Public Hearing
 - Decision
- XXXVI. Retinoids – Topical**
 - Discussion
 - Public Hearing
 - Decision

XXXVII. Respiratory Monoclonal Antibodies

- Discussion
- Public Hearing
- Decision

XXXVIII. Ulcerative Colitis Agents – Oral

- Discussion
- Public Hearing
- Decision

XXXIX. Ulcerative Colitis Agents - Rectal

- Discussion
- Public Hearing
- Decision

E. Preferred Drug List Classes for June/July

- Process Discussion
- Therapeutic classes/to be announced at the meeting

1:30 pm

LUNCH

1:45-2:00

Program Utilization Information - Conduent Update

Olivia Rush

2:00-2:15

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*
- *Opioid Roadmap*

Informal comments will be accepted from members of the audience at various points on the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: Thursday, June 20, 2019

Missouri Coalition for Community Behavioral Healthcare,
221 Metro Dr. Lower Level, CEO Room